Compassionate use: A story of ethics and science in the development of a new drug

Perspectives in Biology and Medicine

Volumn 54, Issue 3, 2011, Pages 304-315

  Buhles, William C ^a  

^a Clinical Science Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN HERPESVIRUS 5;

EID: 80052575812     PISSN: 00315982     EISSN: None     Source Type: Journal    
DOI: 10.1353/pbm.2011.0027     Document Type: Article

References (29)

1. Associated Press (AP). 1989. Panel backs drug to fight eye danger. NY Times,May 4.
2. Barré-Sinoussi, F., et al. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868-71.
3. Buhles, W. C., et al. 1988. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: Experience in 314 immunocompromised patients. Rev Infect Dis 10(suppl. 3):S495-S506.
4. Cimons, M. 1989.Too much too fast? Drug rules: AIDS spurs new climate. LA Times, Sept. 7.
5. Cochrane, M. 2004. When AIDS began: San Francisco and the making of an epidemic. New York: Routledge.
6. Collaborative DHPG Treatment Study Group. 1986.Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. New Eng J Med 314:801-805.
7. Delaney, M. 2006. Interview. http://www.pbs.org/wgbh/pages/frontline/aids/interviews/delaney.html.
8. DeParle, J. 1990. Rude, rash, effective,Act-Up shifts AIDS policy. NY Times, Jan. 3.
9. Dieterich, D.T., et al. 1993. Ganciclovir treatment of cytomegalovirus colitis in AIDS:A randomized, double-blind, placebo-controlled multicenter study. J Infect Dis 167:278-82.
10. Epstein, S. 1996. Impure science: AIDS, activism, and the politics of knowledge. Berkeley:Univ. of California Press.
11. Flieger, K. 1993. FDA finds new ways to speed treatments to patients. FDA Consumer, Oct.
12. Gottlieb, M. S., et al. 1981. Pneumocystis pneumonia: Los Angeles. MMWR Morb Mortal Wkly Rep 30:250-52.
13. Grmek, M.D. 1990.History of AIDS: Emergence and origin of a modern pandemic. Princeton: Princeton Univ. Press.
14. Harrington, M., et al. 1989. Blinded by science: DHPG and the conflict between "clean data" and humane health care. Int Conf AIDS June 4-9 Montreal; 5:1017 (abstract no. Th.G.P.11).
15. Holland, G. N., et al. 1989.A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Arch Ophthal 107:1759-1766.
16. Jabs, D. A., et al. 1989. Cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthal 107:75-80.
17. James, J. S. 1988. CMV retinitis-ganciclovir, foscarnet, and other treatments: Background, history, and emerging controversy. AIDS Treatment News, no. 071, Dec. 16.
18. Kolata, G. 1989a. FDA approves the use of an experimental drug for AIDS patients' eye infections. NY Times, March 3.
19. Kolata, G. 1989b. FDA gives quick approval to two drugs to treat AIDS. NY Times, June 27.
20. Martin, J. C., et al. 1983. 9-(1,3-dihydroxy-2-propoxymethyl)guanine: A potent and selective antiherpes agent. J Med Chem 26(5):759-761.
21. Miller, F. G., and S. Joffe. 2011. Equipoise and the dilemma of randomized clinical trials. New Eng J Med 363:476-480.
22. Shilts, R. 1987. And the band played on. NewYork: St.Martin's Press.
23. Spector, S.A., et al. 1993.A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis 168: 557-63.
24. Spector, S.A., et al. 1996.Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. New Eng J Med 334:1491-1497.
25. Thompson, D., et al. 1989.Medicine: Drugs from the underground. Time, July 10.
26. United Press International (UPI). 1989. AIDS activists demand drug to prevent blindness. CDC HIV/STD/TB Prevention News Update, Jan. 26.
27. U.S. Food and Drug Administration (FDA). 1987.Transcript of the Anti-Infective Drugs Advisory Committee, Oct. 26-27, 1987.
28. U.S. Food and Drug Administration (FDA). 2009. Physician request for a single patient IND for compassionate or emergency use. http://www.fda.gov/Drugs/Development ApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm107434.htm.
29. U.S. Food and DrugAdministration (FDA). 2011. For consumers:Treatment IND. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/PatientInvolvement/ucm123872.htm.